Literature DB >> 17878649

Lymphangioleiomyomatosis diagnosed by immunocytochemical and genetic analysis of lymphangioleiomyomatosis cell clusters found in chylous pleural effusion.

Michihiro Hirama1, Ryo Atsuta, Keiko Mitani, Toshio Kumasaka, Yoko Gunji, Shin-ichi Sasaki, Akihiko Iwase, Kazuhisa Takahashi, Kuniaki Seyama.   

Abstract

A 37-year-old woman presented with a cough and discomfort in the chest. Computed tomography revealed the right pleural effusion and a number of cysts in the lungs. Thoracentesis revealed LAM cell clusters (LCC) in chylous pleural effusion, confirmed by immunocytochemical examinations showing that the cells at the center of cluster were LAM cells positive for alpha-smooth muscle actin and HMB45 and the outer layer was lymphatic endothelium cells. When LCC were cultured in vitro, the loss of heterozygosity of TSC2 markers was detected. This case illustrates that LAM can be diagnosed by the identification of LCC without an invasive biopsy if complicated with chylous effusion.

Entities:  

Mesh:

Year:  2007        PMID: 17878649     DOI: 10.2169/internalmedicine.46.0225

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis.

Authors:  Nishant Gupta; MeiLan K Han; Francis X McCormack
Journal:  Ann Am Thorac Soc       Date:  2015-08

2.  mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.

Authors:  Jane Yu; Elizabeth Petri Henske
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

3.  Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis.

Authors:  Riffat Meraj; Kathryn A Wikenheiser-Brokamp; Lisa R Young; Sue Byrnes; Francis X McCormack
Journal:  Front Med       Date:  2012-12-07       Impact factor: 4.592

4.  Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.

Authors:  Atsushi Fujita; Katsutoshi Ando; Etsuko Kobayashi; Keiko Mitani; Koji Okudera; Mitsuko Nakashima; Satoko Miyatake; Yoshinori Tsurusaki; Hirotomo Saitsu; Kuniaki Seyama; Noriko Miyake; Naomichi Matsumoto
Journal:  Hum Genet       Date:  2015-11-12       Impact factor: 4.132

5.  Effusion cytology: an effective method for the diagnosis of pulmonary lymphangioleiomyomatosis.

Authors:  Daming Fan; Li Ding; Hui Liu; Jigang Wang; Wenwen Ran; Yujun Li; Dongliang Lin
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

6.  Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.

Authors:  Nishant Gupta; Geraldine A Finlay; Robert M Kotloff; Charlie Strange; Kevin C Wilson; Lisa R Young; Angelo M Taveira-DaSilva; Simon R Johnson; Vincent Cottin; Steven A Sahn; Jay H Ryu; Kuniaki Seyama; Yoshikazu Inoue; Gregory P Downey; MeiLan K Han; Thomas V Colby; Kathryn A Wikenheiser-Brokamp; Cristopher A Meyer; Karen Smith; Joel Moss; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

7.  Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.

Authors:  Izabela A Malinowska; Nancy Lee; Vidhya Kumar; Elizabeth A Thiele; David Neal Franz; Stephen Ashwal; Arthur Sagalowsky; Francis J Dimario; Drew Cutler; Darcy Krueger; Susana Camposano; Jan Paolini; Sandra L Dabora
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

8.  Lamstatin--a novel inhibitor of lymphangiogenesis derived from collagen IV.

Authors:  Markus Weckmann; Lyn Margaret Moir; Caroline Akemi Heckman; Judith Lee Black; Brian Gregory Oliver; Janette Kay Burgess
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

9.  Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Authors:  Ho Yin Ng; Brian Gregory George Oliver; Janette Kay Burgess; Vera P Krymskaya; Judith Lee Black; Lyn M Moir
Journal:  J Cell Mol Med       Date:  2015-08-18       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.